(CSE:MDM) (FSE: 2M0) (OTCQB:MRPHF)

KELOWNA, BC, Dec. 28, 2017 /CNW/ – Marapharm Ventures Inc., “Marapharm”, is pleased to announce that it has qualified to upgrade from the OTCQB Venture Market in the United States to the OTCQX Best Market. Marapharm will begin trading on OTCQX on January 2, 2018 under the ticker symbol MRPHF.

OTCQX enables companies to provide investors with transparent trading information as well as convenient access to the company’s news and financial disclosure. OTC Markets Group Inc. operates the OTCQX, OTCQB and Pink markets for 10,000 US and global securities. Through the OTC Link ATS, a diverse network of broker dealers is connected that provide liquidity and execution services. Investors in the US can find current financial disclosure and Real Time Level 2 quotes for the company on www.otcmarkets.com.

“OTCQX provides much more exposure and deeper access to US investors. This is a new market for us to share the Marapharm story with new people in the New Year,” Linda Sampson, Marapharm CEO.

ABOUT MARAPHARM VENTURES INC.

Marapharm is a publicly traded company primarily investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California. They actively seek expansion opportunities worldwide.

STOCK EXCHANGES:

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in  Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.

Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

MARIJUANA INDUSTRY INVOLVEMENT:

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.

Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm’s ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm’s business is conducted in a manner consistent with state law and is in compliance with licensing requirements.

Copies of licenses are posted on Marapharm’s website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.

FORWARD – LOOKING STATEMENTS:

Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/December2017/28/c1552.html